1. Home
  2. ATYR vs LDI Comparison

ATYR vs LDI Comparison

Compare ATYR & LDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • LDI
  • Stock Information
  • Founded
  • ATYR 2005
  • LDI 2010
  • Country
  • ATYR United States
  • LDI United States
  • Employees
  • ATYR N/A
  • LDI N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • LDI Finance: Consumer Services
  • Sector
  • ATYR Health Care
  • LDI Finance
  • Exchange
  • ATYR Nasdaq
  • LDI Nasdaq
  • Market Cap
  • ATYR 290.6M
  • LDI 221.2M
  • IPO Year
  • ATYR 2015
  • LDI 2021
  • Fundamental
  • Price
  • ATYR $3.34
  • LDI $1.14
  • Analyst Decision
  • ATYR Strong Buy
  • LDI Sell
  • Analyst Count
  • ATYR 6
  • LDI 3
  • Target Price
  • ATYR $18.60
  • LDI $1.98
  • AVG Volume (30 Days)
  • ATYR 1.1M
  • LDI 809.4K
  • Earning Date
  • ATYR 05-07-2025
  • LDI 05-06-2025
  • Dividend Yield
  • ATYR N/A
  • LDI N/A
  • EPS Growth
  • ATYR N/A
  • LDI N/A
  • EPS
  • ATYR N/A
  • LDI N/A
  • Revenue
  • ATYR N/A
  • LDI $1,039,763,000.00
  • Revenue This Year
  • ATYR $551.06
  • LDI $32.81
  • Revenue Next Year
  • ATYR $2,144.84
  • LDI $16.35
  • P/E Ratio
  • ATYR N/A
  • LDI N/A
  • Revenue Growth
  • ATYR N/A
  • LDI 15.41
  • 52 Week Low
  • ATYR $1.42
  • LDI $1.01
  • 52 Week High
  • ATYR $4.66
  • LDI $3.23
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 51.21
  • LDI 47.75
  • Support Level
  • ATYR $3.06
  • LDI $1.02
  • Resistance Level
  • ATYR $3.67
  • LDI $1.21
  • Average True Range (ATR)
  • ATYR 0.25
  • LDI 0.08
  • MACD
  • ATYR 0.01
  • LDI 0.02
  • Stochastic Oscillator
  • ATYR 46.77
  • LDI 54.76

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

Share on Social Networks: